Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PEGCETACOPLAN for Age-related macular degeneration: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 23 adverse event reports in the FDA FAERS database where PEGCETACOPLAN was used for Age-related macular degeneration.

Most Reported Side Effects for PEGCETACOPLAN

Side Effect Reports % Deaths Hosp.
Fatigue 135 9.9% 1 44
Visual impairment 125 9.1% 0 4
Haemoglobin decreased 106 7.7% 1 51
Haemolysis 100 7.3% 1 57
Off label use 97 7.1% 9 35
Vitreous floaters 78 5.7% 0 4
Breakthrough haemolysis 67 4.9% 1 18
Headache 66 4.8% 2 25
Product dose omission issue 59 4.3% 2 26
Uveitis 59 4.3% 0 0
Covid-19 56 4.1% 1 21
Vitritis 55 4.0% 0 5
Choroidal neovascularisation 52 3.8% 1 2
Eye inflammation 52 3.8% 0 2
Drug ineffective 49 3.6% 8 15

Other Indications for PEGCETACOPLAN

Paroxysmal nocturnal haemoglobinuria (559) Product used for unknown indication (352) Dry age-related macular degeneration (326) C3 glomerulopathy (27) Macular degeneration (13) Neovascular age-related macular degeneration (13)

Other Drugs Used for Age-related macular degeneration

AFLIBERCEPT (2,220) RANIBIZUMAB (1,982) BEVACIZUMAB (574) BROLUCIZUMAB-DBLL (445) VERTEPORFIN (256) LUCENTIS (248) FARICIMAB\FARICIMAB-SVOA (185) EYLEA (156) FARICIMAB-SVOA (117) BROLUCIZUMAB (73)

Related Pages

PEGCETACOPLAN Full Profile All Age-related macular degeneration Drugs PEGCETACOPLAN Demographics PEGCETACOPLAN Timeline